DIRECT ACTING ANTIVIRAL (DAA) THERAPY IN REAL WORLD HCV COMPENSATED CIRRHOSIS
Aim: Given the effectiveness of direct acting antiviral (DAA) therapy in patients with chronic hepatitis C virus (HCV) infection, we aimed to describe the demographic, clinical and biological characteristics of our patients who received treatment with direct acting antivirals during December 2015-October 2016 and September 2017-January 2018. Material and Methods: We performed a prospective study of 186 patients with chronic hepatitis C who have undergone treatment with paritaprevir/ombitasvir/ritonavir and dasabuvir with or without ribavirin during December 2015 - October 2016 (group 1) and September 2017 - January 2018 (group 2). The inclusion and exclusion criteria were established according to the national protocol. Demographic, clinical and biological data were recorded before starting treatment. All patients underwent upper gastrointestinal endoscopy and abdominal ultrasound. The determination of HCV genotypes and subtypes was realized by the Abbott RealTime HCV assay. The presence of mild or advanced fibrosis, cirrhosis, the viral necro inflammatory activity and the presence of nonalcoholic steatohepatitis (NASH) were assessed by FibroMax non-invasive liver tests: ActiTest, FibroTest and NashTest. Results: The mean age was 58.7 years for the first group and 59.6 for the second group, with the predominance of female gender in both cases. Genotype 1b was present exclusively in the first group. Median HCV RNA at baseline was 1 264 123.180 IU/mL for the first group and 1 678 718.97 IU/mL for the second group. No patients were HBV or HIV co-infected. Most patients were naive to interferon therapy. The comorbidity rate was increased in both groups: 28.82% vs. 49.3% had cardiovascular diseases, 23.41% vs. 14.66% had diabetes mellitus (with or without insulin requirement), 2.7% vs. 10.6% had thyroid dysfunction, 1.8% vs. 0% had dermatological disease, 0.9% vs. 5.33% had psychiatric disorders, 1.8% vs. 1.33% had a history of cured neoplasm, 1.8% vs. 2.66% had pulmonary diseases and 0.9% vs. 1.33% had hematological diseases. No patient had a history of treated hepatocellular carcinoma. In both groups, the maximum number of drugs administered simultaneously with the antiviral therapy was 4. The necro inflammatory activity assessed by ActiTest highlights a high rate for severe activity for both groups - 66.6%. The prevalence of concomitant NASH assessed by NashTest (N2-severe inflammation) was 50% in group 1 and 53.3% in group 2. There were slight differences between the two groups in terms of biological constants, but without any statistical significance. Conclusions: The partial results of our study show a higher prevalence of HCV infection among people born between 1946 and 1964 (baby boom generation), especially women. In this geographical area, genotype 1b was found exclusively. Most patients, naïve to interferon therapy, associate numerous comorbidities and simultaneous treatments that may decrease adherence to therapy due to the possibility of significant drug-drug interactions, requiring optimal therapeutic management and close monitoring.
2. Chen SL, Morgan TR. The Natural History of Hepatitis C Virus (HCV) Infection. Int J Med Sci 2006;3(2):47-52.
3. Hanafiah KM, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infec-tion: New estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57(4): 1333-1342.
4. Boesecke C, Wasmuth JC. Hepatitis C. In: Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H, editors. Hepatology: a clinical textbook. Germany: Medizin Fokus Verlag 2016, 55-65.
5. Tsoulfas G, Goulis I, Giakoustidis D, et al. Hepatitis C and liver transplantation. Hippokratia 2009;13(4):211-215.
6. Roche B, Samuel T. Hepatitis C virus treatment pre- and post-liver transplantation. Liver Int 2012;32(1):120-128.
7. Alter HJ, Purcell RH, Shih JW, et al. Detection of antibody to hepatitis C virus in prospectively fol-lowed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989; 321: 1494-500.
8. Vogel M, Deterding K, Wiegand J, et al. Initial presentation of acute hepatitis C virus (HCV) infection among HIV-negative and HIV-positive individuals-experience from 2 large German networks on the study of acute HCV infection. Clin Infect Dis 2009; 49: 317-319.
9. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
10. Kupfer B. HCV Virology. In: Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H, editors. Hepatology: a clinical textbook. Germany: Medizin Fokus Verlag 2016, 105-123.
11. Gafton B, Porumb V, Ungurianu S, Marinca MV, Cocea C, Croitoru A, Balan G, Miron N, Ciuleanu TE, Miron L. Hepatocellular Carcinoma: insight in the biological treatment beyond sorafenib. J BUON 2014; 19(4): 858-866.
12. Desmond CP, Roberts SK, Dudley F, Mitchell J, Day C, Nguyen S, Pianko S. Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting. J Viral Hepat 2006; 13(5): 311-315.
13. Lange C, Sarrazin C. Hepatitis C: Diagnostic Tests. In: Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H, editors. Hepatology: a clinical textbook. Germany: Medizin Fokus Verlag 2016, 223-244.
14. Cornberg M, Honer du Siederdissen C, Maasoumy B, et al. Standard therapy of Chronic Hepatitis C Virus Infection. In: Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H, editors. Hepatology: a clinical textbook. Germany: Medizin Fokus Verlag 2016, 247-301
15. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370: 1973-1982.
16. Sherman KE, Sulkowski MS, Zoulim F, et al. Follow-up of svr durability and viral resistance in patients with chronic hepatitis c treated with telaprevir-based regimens: interim analysis of the extend study. Hepatology 2011;54: 485-486.
18. Lange C, Sarrazin C. Hepatitis C: New drugs. In: Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H. Hepatology: a clinical textbook. Germany: Medizin Fokus Verlag 2017, 323-346.
19. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribu-tion of the hepatitis C virus infection. J Hepatol 2014; 61: 45-57.
20. Grigorescu M. HCV Genotype 1 is Almost Exclusively Present in Romanian Patients with Chronic Hepatitis C. J Gastrointestin Liver Dis March 2009; 18(1):45-50.
21. Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource. Hepatology 2014; 59: 318-327.
22. Shi W, Freitas IT, Zhu C, et al. Recombination in hepatitis C virus: identification of four novel naturally occurring inter-subtype recombinants. PLoS One 2012; 7: e41997.
23. Ruta S, Sultana C, Oprea C, et al. HCV non-1b genotypes in injecting drug users from Romania. J Infect Dev Ctries 2016; 10(5): 523-527.
24. Lens S, Pawlotsky JM. Treatment of chronic hepatitis C in 2017. What is the future? (pp.43-50) In: Hernandez-Gea V, Lens S, Bruix J, Forns X, Garcia-Pagan JC, Narvasa M, Gines P. Therapy in liver diseases 2017. Spain: Fundacio Clinic Barcelona 2017, 43-50.
25. Asselah T, Kowdley KV, Zadeikis N, Wang S, Hassanein T, Horsmans Y et al. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. Clin Gastroenterol Hepatol 2018; 16(3): 417-426.
26. Cornberg M, Honer du Siederdissen C, Maasoumy B, et al. Standard therapy of Chronic Hepatitis C Virus Infection. In: Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H, editors. Hepatology: a clinical textbook. Germany: Medizin Fokus Verlag 2017, 252-321.
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.
COPYRIGHT TRANSFER FORM FOR
REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /
THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI
We, the undersigned authors of the manuscript entitled
warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.
- we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
- the manuscript does not break the intellectual property rights of any other person.
- we have read the submitted version of the manuscript and we are fully responsible for the content.
Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):
N.B. All the authors must sign this form